Since these early studies, it is now well established that the anti‐tumour function of the immune system is largely dependent on cytotoxic CD8+ T lymphocytes (CTL) that directly kill cancer cells through recognition of tumour antigens that are presented alongside major histocompatibility complex (MHC) class I molecules. This evidence concerns the gene CD8A and cancer.